Mixed movements were observed in the premarket healthcare stocks on Wednesday, with the Health Care Select Sector SPDR Fund (XLV) falling by 0.1%, while the iShares Biotechnology ETF (IBB) rose by 0.2%.
Moderna (NASDAQ:MRNA) experienced a significant increase in value, gaining over 6% after announcing its expectation to add $10 billion to $15 billion in annual sales by 2028. This anticipated surge is tied to the introduction of new products targeting oncology, as well as rare and latent diseases.
Rocket Pharmaceuticals (NASDAQ:NASDAQ:RCKT) also saw a substantial rise, with its value going up more than 39%. This followed their announcement of pricing an underwritten public offering poised to generate gross proceeds of approximately $175 million.
Meanwhile, Mainz Biomed (NASDAQ:MYNZ) reported a climb of over 9% after revealing positive results from a clinical trial. The trial, which assessed the potential inclusion of novel gene expression biomarkers in its colorectal cancer test ColoAlert, showed a sensitivity for the disease of 94%, specificity of 97%, and sensitivity for advanced adenoma of 81%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.